胃肠道间质肿瘤的发病机制及靶向治疗研究进展  

Progress in the pathogenesis and targeted therapy of gastrointestinal stromal tumors

作　　者：王书宝[1] 王哲[1] 贺明[2] 蒋晶晶[3] WANG Shubao;WANG Zhe;HE Ming;JIANG Jingjing(Department of Pathology,Shengjing Hospital of China Medical University,Shenyang 110034,China;Department of Orthopedics,Shengjing Hospital of China Medical University,Shenyang 110034,China;Department of Anesthesiology,Shengjing Hospital of China Medical University,Shenyang 110034,China)

机构地区：[1]中国医科大学附属盛京医院病理科,沈阳110034 [2]中国医科大学附属盛京医院骨科,沈阳110034 [3]中国医科大学附属盛京医院麻醉科,沈阳110034

出　　处：《中国医科大学学报》2023年第6期543-548,共6页Journal of China Medical University

基　　金：国家自然科学基金青年科学基金(81601692);辽宁省教育厅科学研究项目(JCZR202013);辽宁省自然科学基金(2020-MS-177)。

摘　　要：胃肠道间质肿瘤(GIST)是罕见的间质来源的肿瘤。基因突变在GIST发病机制中起着关键作用,靶向治疗已成为GIST的主要辅助治疗手段。通过对酪氨酸激酶抑制剂(TKI)类药物耐药机制信号通路的深入研究,将其中一些分子作为治疗靶点,推动TKI类药物的更新迭代,也为GIST患者提供了更多治疗方法的选择,使部分GIST患者的生存期和生活质量获得显著改善。本文对GIST的发病机制及靶向治疗的研究进展进行综述。Gastrointestinal stromal tumors(GISTs)are rare tumors of stromal origin.Gene mutations play a key role in the pathogenesis of GISTs,and molecular targeted therapy has become the main adjuvant treatment option for them.An in-depth study of the signaling pathways of tyrosinase kinase inhibitor(TKI)drug resistance is driving the evolution of TKI drugs in efforts to provide more treatment options for patients with GISTs.As a result,the life span and quality of life will significantly improve in some patients with GISTs.In this paper,the progress in the pathogenesis of GISTs and associated targeted therapy is reviewed.

关 键 词：胃肠道间质肿瘤 发病机制 基因突变 靶向治疗 

分 类 号：R735[医药卫生—肿瘤]